NeuroSense Therapeutics Ltd.
NRSNNeuroSense Therapeutics reported modestly narrower losses in FY2025 amid sustained R&D investment in PrimeC for ALS, with operating cash burn improving due to tighter expense control while advancing toward Phase 3 following positive PARADIGM biomarker data.
NASDAQ
Healthcare
Biotechnology
$0.83
+0.07(9.22%)
52W $0.71 – $2.49
AI-generated
NeuroSense Therapeutics reported modestly narrower losses in FY2025 amid sustained R&D investment in PrimeC for ALS, with operating cash burn improving due to tighter expense control while advancing toward Phase 3 following positive PARADIGM biomarker data.
$20MMkt Cap
—Rev TTM
-$8MNI TTM
-2.2xP/E TTM
Latest Earnings
20-F
FY FY2025Mar 30, 2026NeuroSense Therapeutics reported modestly narrower losses in FY2025 amid sustained R&D investment in PrimeC for ALS, with operating cash burn improving due to tighter expense control while advancing toward Phase 3 following positive PARADIGM biomarker data.
Fundamentals
How The Business Makes Money
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Industry Biotechnology
Company Profile
CIK0001875091
ISINIL0011809592
CUSIPM74240108
Phone972 9 799 6183
AddressBuilding B, Herzliya, 4672562, IL
SEC EDGAR